Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China DOI Creative Commons
Qian Yang, Zihao Zou, Wei Cao

et al.

COVID, Journal Year: 2023, Volume and Issue: 3(12), P. 1707 - 1720

Published: Nov. 21, 2023

The COVID-19 pandemic significantly disrupted global healthcare systems. impacts of SARS-CoV-2 infection on urticaria and its management are unknown. This study aimed to collect information about patients with infected investigate the impact severity, course, treatment better support recovery. was a questionnaire-based SARS-CoV-2. Changes in severity (measured activity score (UAS)), were assessed before, during, after infection. mean (±SD) UAS scores 5.17 ± 1.67, 4.23 1.98, 4.37 1.93 infection, respectively (F = 8.839, p < 0.01). median (IQR) wheal 0.464 (0.464, 0.763), (0.138, 0.763) (Kruskal–Wallis H-test, H 12.230, 0.02). pruritus 0.695 (0.395, 0.695), 0.394 (0.123, 0.695) 21.001, Within limitations questionnaire study, appears improve during worsens slightly recovery, frequency Western medicine use increases.

Language: Английский

Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema DOI
Pavel V. Chernyshov, A.Y. Finlay, Lucía Tomás Aragonés

et al.

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2024, Volume and Issue: unknown

Published: June 10, 2024

Abstract The European Academy of Dermatology and Venereology (EADV) Task Forces on quality life (QoL) patient‐oriented outcomes urticaria angioedema recommendations for the assessment Health‐related (HR) QoL in all patients with research practice are as follows: to use DLQI adults CDLQI children dermatology‐specific CU‐Q2oL a disease‐specific HRQoL instruments urticaria; generic provide comparison data non‐dermatologic diseases, or compare healthy volunteers general population; select validated appropriate age limits; present exact numeric results; correct title any instrument should be used, along its abbreviation reference original publication, where possible. EADV TFs discourage non‐validated modified that have not undergone standard validation.

Language: Английский

Citations

2
COVID-19 and Its Impact on Common Diseases in the Allergy Clinics DOI
Emek Kocatürk, Elissa M. Abrams, Marcus Maurer

et al.

The Journal of Allergy and Clinical Immunology In Practice, Journal Year: 2023, Volume and Issue: 11(11), P. 3289 - 3303

Published: Sept. 1, 2023

Language: Английский

Citations

5
A Practical Approach to Diagnosing and Managing Chronic Spontaneous Urticaria DOI Creative Commons
Adam Friedman, Shawn G. Kwatra, Gil Yosipovitch

et al.

Dermatology and Therapy, Journal Year: 2024, Volume and Issue: 14(6), P. 1371 - 1387

Published: May 17, 2024

Chronic spontaneous urticaria (CSU) is an unpredictable inflammatory skin condition characterized by the onset of itchy wheals, angioedema, or both, which occurs for longer than 6 weeks overall. Despite relatively straightforward diagnostic algorithm CSU, relying primarily on a detailed medical history and only limited laboratory tests, patients often wait years to be diagnosed, with many cycling through different healthcare practitioners before diagnosis made. Even then, current treatment options CSU are limited, approximately half resistant standard-of-care second-generation antihistamines at standard higher doses. As such, there unmet need improved, streamlined management CSU. Here, we review evidence-based consider required steps workup, provide practical, real-world advice improve timely care this debilitating disease.

Language: Английский

Citations

1
Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement DOI
Pavel V. Chernyshov, L. Tomás-Aragonés, Torsten Zuberbier

et al.

International Journal of Dermatology, Journal Year: 2024, Volume and Issue: 63(12), P. 1657 - 1667

Published: July 4, 2024

In this study, the European Academy of Dermatology and Venereology (EADV) Task Forces on Quality Life Patient-Oriented Outcomes Urticaria Angioedema has examined Health-Related (HRQoL) measurement in treatment urticaria. The Index was most frequently used HRQoL instrument clinical trials Many reports urticaria gave no exact numeric results related to changes, making clear conclusions comparisons with other studies impossible. interpretation impairment data is more difficult when assessed by instruments without severity stratification systems. minimal clinically significant difference (MCID) a oriented relevant parameter than depending statistically changes scores. Therefore, using established MCID practice preferred.

Language: Английский

Citations

1
Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China DOI Open Access
Qian Yang, Zihao Zou, Wei Cao

et al.

Published: Nov. 3, 2023

Abstract: The COVID-19 pandemic significantly disrupted global healthcare systems. impacts of SARS-CoV-2 infection on urticaria and its management are unknown. To collect information about patients with infected to investigate the impact severity, course, treatment better support recovery. This was a questionnaire-based study SARS-CoV-2. Changes in severity (measured activity score (UAS)), were assessed before, during, after infection. Mean (&plusmn; SD) UAS scores 5.17 &plusmn; 1.67, 4.23 1.98, 4.37 1.93 infection, respectively (F = 8.839, p &lt; 0.01). median (IQR) wheal 0.464 (0.464, 0.763), (0.138, 0.763) (Kruskal-Wallis H-test, H=12.230, 0.02). pruritus 0.695 (0.395, 0.695), 0.394 (0.123, 0.695) H 21.001, Within limitations questionnaire study, appears improve during worsens slightly recovery, frequency Western medicine use increases.

Language: Английский

Citations

1
Can Vaccinations Trigger or Exacerbate Chronic Urticaria? DOI Open Access
Young‐Min Ye

Allergy Asthma and Immunology Research, Journal Year: 2024, Volume and Issue: 16(6), P. 567 - 567

Published: Jan. 1, 2024

Language: Английский

Citations

0
Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China DOI Creative Commons
Qian Yang, Zihao Zou, Wei Cao

et al.

COVID, Journal Year: 2023, Volume and Issue: 3(12), P. 1707 - 1720

Published: Nov. 21, 2023

The COVID-19 pandemic significantly disrupted global healthcare systems. impacts of SARS-CoV-2 infection on urticaria and its management are unknown. This study aimed to collect information about patients with infected investigate the impact severity, course, treatment better support recovery. was a questionnaire-based SARS-CoV-2. Changes in severity (measured activity score (UAS)), were assessed before, during, after infection. mean (±SD) UAS scores 5.17 ± 1.67, 4.23 1.98, 4.37 1.93 infection, respectively (F = 8.839, p < 0.01). median (IQR) wheal 0.464 (0.464, 0.763), (0.138, 0.763) (Kruskal–Wallis H-test, H 12.230, 0.02). pruritus 0.695 (0.395, 0.695), 0.394 (0.123, 0.695) 21.001, Within limitations questionnaire study, appears improve during worsens slightly recovery, frequency Western medicine use increases.

Language: Английский

Citations

0